Cerium dioxide nanoparticles increase immunogenicity of the influenza vaccine
| Autor: | Olga S. Ivanova, A. B. Shcherbakov, Olga Shydlovska, Alla P. Mironenko, Larysa V. Radchenko, Mykola Ya Spivak, Alexander E. Baranchikov, Nadezhda Zholobak, Vladimir Ivanov, Andrey I. Marinin |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Influenza vaccine 02 engineering and technology Antibodies Viral Virus Mice 03 medical and health sciences иммуногенность Influenza A Virus H1N1 Subtype Microscopy Electron Transmission Virology Animals Medicine Seroconversion Pharmacology Hemagglutination assay business.industry Influenza A Virus H3N2 Subtype Immunogenicity Antibody titer вакцины для профилактики гриппа Cerium Hemagglutination Inhibition Tests 021001 nanoscience & nanotechnology Vaccination Influenza B virus диоксид церия 030104 developmental biology Vaccines Inactivated Immunization Influenza Vaccines Antibody Formation Immunology Nanoparticles Female 0210 nano-technology business наноматериалы |
| Zdroj: | Antiviral research. 2016. Vol. 127. P. 1-9 |
| ISSN: | 0166-3542 |
| DOI: | 10.1016/j.antiviral.2015.12.013 |
| Popis: | We have demonstrated the influence of cerium dioxide nanoparticles on the immunogenicity of the influenza vaccine on an example of liquid split inactivated Vaxigrip vaccine. Antibody titers were analyzed using the hemagglutination inhibition (HI) assay. Seroprotection, seroconversion, the geometric mean titers (GMTs) and the factor increase (FI) in the GMTs were calculated. The effect of nano-ceria surface stabilizer on the enhancement of immunogenicity was shown. The vaccine modified by citrate-stabilized nano-ceria, in contrast to a non-modified Vaxigrip vaccine, did not provide an adequate level of seroprotection, and seroconversion after vaccination was 66.7% on days 49–63 for virus strain А(H1N1) and 100% on day 49 for virus strain B/Yamagata. For the low immunogenic influenza B virus, the rise in antibody titers (GMT/IF) was 24.38/3.28 after the first injection and 50.40/6.79 on day 49. For the vaccine modified by non-stabilized nano-ceria, for all virus strains under study, on day 63, upon immunization notable levels of seroprotection, seroconversion and GMT/IF were registered (higher than for the non-modified Vaxigrip vaccine). The successful attempt to modify the influenza vaccine demonstrates the possible ways of increasing the specific activity of vaccines using nano-ceria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect